WO2022190018 - NOVEL DARPIN BASED CD123 ENGAGERS

National phase entry:
Publication Number WO/2022/190018
Publication Date 15.09.2022
International Application No. PCT/IB2022/052128
International Filing Date 09.03.2022
Title [English] NOVEL DARPIN BASED CD123 ENGAGERS [French] NOUVEAUX AGENTS DE MISE EN CONTACT DE CD123 À BASE DE DARPIN
Applicants ** MOLECULAR PARTNERS AG Wagistrasse 14 8952 Zurich-Schlieren, CH
Inventors ** REICHEN, Christian Hirzenbachstrasse 68 8952 Zurich, CH RESCHKE, Nina Muttenzerstrasse 60 4127 Birsfelden, CH SCHLERETH, Bernd Schulstrasse 82 8952 Schlieren, CH
Priority Data 63/158,539  09.03.2021  US 63/173,227  09.04.2021  US 63/265,187  09.12.2021  US
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 1802
EPO Filing, Examination 10327
Japan Filing 564
South Korea Filing 645
USA Filing, Examination 6435
MasterCard Visa
Total: 19773
The term for entry into the National Phase has expired. This quotation is for informational purposes only.

Abstract [English] The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD123. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g., acute myeloid leukemia (AML), in a mammal, including a human. [French] La présente invention concerne des protéines de liaison recombinées comprenant un domaine de répétition d'ankyrine, le domaine de répétition d'ankyrine présentant une spécificité de liaison pour le CD123 humain. De plus, l'invention concerne des acides nucléiques codant de telles protéines de liaison recombinées, des compositions pharmaceutiques comprenant de telles protéines ou de tels acides nucléiques, et l'utilisation de telles protéines de liaison, de tels acides nucléiques ou de telles compositions pharmaceutiques dans des méthodes de traitement ou de diagnostic de maladies, telles que le cancer, par exemple, la leucémie myéloïde aiguë (LAM) chez un mammifère, notamment un être humain.